Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ImmunityBio (IBRX) Non Operating Income (2016 - 2026)

ImmunityBio has reported Non Operating Income over the past 12 years, most recently at -$1.7 million for Q4 2025.

  • Quarterly Non Operating Income rose 97.6% to -$1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$22.9 million through Dec 2025, up 67.01% year-over-year, with the annual reading at -$2.2 million for FY2025, 96.87% up from the prior year.
  • Non Operating Income was -$1.7 million for Q4 2025 at ImmunityBio, down from -$187000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $7.5 million in Q4 2021 and troughed at -$69.4 million in Q4 2024.
  • The 5-year median for Non Operating Income is -$56000.0 (2023), against an average of -$7.4 million.
  • Year-over-year, Non Operating Income skyrocketed 918.81% in 2021 and then tumbled 123547.06% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $7.5 million in 2021, then crashed by 412.98% to -$23.4 million in 2022, then soared by 99.7% to -$71000.0 in 2023, then crashed by 97700.0% to -$69.4 million in 2024, then soared by 97.6% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Non Operating Income are -$1.7 million (Q4 2025), -$187000.0 (Q3 2025), and -$21.0 million (Q2 2025).